Novo Nordisk Boosts Forecast on Soaring GLP-1 Sales

Novo Nordisk A/S raised its annual forecast, citing increased sales expectations for its GLP-1 drugs used to treat obesity and diabetes. The company had previously raised its forecast once earlier in 2026. The updated projection reflects higher demand for medications including Ozempic and Saxenda.

Next story